BOTHELL, WA, Oct 21, 2011 (MARKETWIRE via COMTEX) --
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced positive safety results from the first five cohorts of Phase I single ascending dose trials of AVI-6002 and AVI-6003, AVI's lead drug candidates being evaluated for the treatment of Ebola virus and Marburg virus, respectively.
Data from five cohorts of the AVI-6002 and AVI-6003 studies were evaluated by an independent Data and Safety Monitoring Board (DSMB), which issued recommendations for both studies to progress as planned to the next highest dosing level after no safety concerns were identified. The Phase I single ascending dose trials are designed to characterize the safety, tolerability and pharmacokinetics of each therapeutic candidate in healthy adult volunteers.
"We are very encouraged that these two drugs, which use our advanced PMOplus(R) chemistry, have demonstrated a favorable safety profile through five cohorts in our dose-escalation studies. These data also suggest that our backbone chemistry may be safe, independent of the specific sequence that is being targeted, and may support applications to other viral targets," said Chris Garabedian, president and CEO of AVI BioPharma.
To date, 25 healthy human subjects (five per group) have been enrolled into five sequential dose groups (0.01, 0.1, 1.0, 3.0 or 6.0 mg/kg) in each of the two studies. Within each group, four subjects received the indicated dose of the therapeutic and one subject received placebo. For each group, safety, clinical laboratory and renal biomarker results through five days after treatment were reviewed by a DSMB. Subjects enrolled in the sixth group for the drug studies will receive 9.0 mg/kg of the therapeutic or placebo. Final, unblinded safety and pharmacokinetic results for all subjects will be available upon completion of the trial
The person doing so has no confidence deep inside themselves and or trying to make others look bad to gain ''revolving world in their circle' NOT a very wise person and a person that is lacking.
THIS IS A GSK VACCINE NOT A TREATMENT FOR THE ALREADY SICK.. AND THIS GSK VACCINE WILL BE TESTED SOON.
The vaccine is being developed by the NIAID in collaboration with health care company GlaxoSmithKline and the United States Army Medical Research Institute for infectious diseases.
The vaccine performed “extremely well” when tested on monkeys, Fauci said.
Fauci said the first three volunteers will be enrolled in the study next week, and the trial will eventually enroll 20 adults ages 18-50. The study will be conducted at NIH headquarters in Bethesda, Md.
Has anyone in any government have a plan?
moving way to slow
Oct. 4, 2012 6:03 AM ET | Includes: AIG, RPM, SRPT, VFC by: SA Editor Miriam Metzinger Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday October 3.
CEO Interview: Chris Garabedian, Sarepta Therapeutics (NASDAQ:SRPT)
A stock that Cramer recommended as a speculative stock on Lightning Round two weeks ago shot up to the stratosphere on Wednesday, rising 200% in a single session. When Cramer got behind it, Sarepta Therapeutics (SRPT) was a $14 stock, and now it has climbed into the $40s. He urged investors not to chase the stock up at these levels, but SRPT is an example of why investors should devote a small portion of their portfolios to speculative stocks. Cramer confessed that, in his 30 years of trading, SRPT has had the biggest one day gain he's ever seen.